GlassScriptPhysician profile
Fred C Umeh
NPI 1114995842
$371,310.76
in general payments reported to CMS, 2019-2025
56 companies · $75K in 2025
The $75K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $37K · 2021: $50K · 2022: $70K · 2023: $69K · 2024: $57K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Food and Beverage: $19K · Travel and Lodging: $13K · Education: $39.57 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,285.00 |
| Food and Beverage | $18,880.92 |
| Travel and Lodging | $12,719.77 |
| Education | $39.57 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $289,089.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $59,470.74 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,761.95 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Allergan, INC. | $3,187.54 | 2019-2020 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Genzyme Corporation | $1,542.34 | 2019-2025 | |
| Grifols USA, LLC | $1,345.26 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $1,196.48 | 2021-2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $969.71 | 2019-2025 | Dupixent |
| Insmed, INC. | $926.03 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $869.98 | 2019-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $869.54 | 2019-2024 | (Ak6) Vest Therapy |
| Jazz Pharmaceuticals INC. | $734.43 | 2019-2024 | |
| Gilead Sciences, INC. | $443.99 | 2022-2024 | |
| Harmony Biosciences LLC | $433.60 | 2020-2024 | Wakix |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $428.89 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Bayer Healthcare Pharmaceuticals INC. | $419.75 | 2019-2023 | |
| Amgen INC. | $359.06 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $355.69 | 2019-2024 | Xolair |
| Paratek Pharmaceuticals, INC. | $315.26 | 2022-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $266.91 | 2019-2024 | Xarelto |
| Mylan Specialty L.P. | $260.58 | 2019-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $247.99 | 2019-2022 | |
| Vapotherm INC | $202.07 | 2019-2023 | Vapotherm |
| Zoll Respicardia, INC. | $169.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $148.29 | 2020-2023 | Airduo Digihaler |
| E.R. Squibb & Sons, L.L.C. | $147.56 | 2022-2023 | Eliquis |
| Pulmonx Corporation | $141.13 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| La Jolla Pharmaceutical Company | $128.60 | 2023 | Giapreza |
| Idorsia Pharmaceuticals US INC | $124.65 | 2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $119.50 | 2025 | |
| Sun Pharmaceutical Industries INC. | $117.77 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $114.53 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $113.85 | 2024 | Sunosi |
| Verona Pharma, INC. | $80.87 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $75.58 | 2025 | Yupelri |
| Baxter Healthcare | $73.33 | 2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Vifor Pharma, INC. | $70.50 | 2024 | Zemaira, Veltassa |
| Electromed, INC. | $68.05 | 2019-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $43.10 | 2023-2024 | Keytruda |
| Sandoz INC. | $35.01 | 2019-2025 | Treprostinil |
| Ethicon INC. | $32.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.07 | 2025 | Acthar |
| Inspire Medical Systems, INC. | $21.48 | 2025 | Inspire |
| Portola Pharmaceuticals, LLC | $19.35 | 2019 | |
| Fisher & Paykel Healthcare INC | $18.96 | 2023 | Fisher & Paykel Healthcare |
| Ani Pharmaceuticals, INC. | $16.67 | 2022 | |
| Inogen, INC. | $16.56 | 2022 | |
| Eisai INC. | $14.95 | 2020 | |
| Circassia INC. | $14.39 | 2019 | |
| Boston Scientific Corporation | $13.34 | 2022 | |
| Shire North American Group INC | $13.01 | 2019 | |
| Nabriva Therapeutics, Plc | $12.93 | 2020 | |
| Pinnacle Biologics, INC | $12.28 | 2021 | |
| Phadia US INC. | $11.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,282.46 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Umeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.